Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
Type:
Application
Filed:
April 12, 2022
Publication date:
August 7, 2025
Inventors:
Shuhei IKEDA, Martin Alexander PAWLICZEK, Eiji KIMURA, Yasushi HATTORI, Marilena PIRA, Javier MIGUELEZ-RAMOS, Norihito TOKUNAGA, Yuhei MIYANOHANA, Yasutaka HOASHI, Yuichi KAJITA, Yoshiteru ITO, Tasuki KOIKE
Abstract: The present invention generally relates to compounds inhibiting dipeptidyl peptidase 1 activity; particularly the invention relates to compounds that are azetidine derivatives, including pharmaceutically acceptable salts thereof, methods of preparing such compounds, and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DPP1 receptors mechanisms, in particular respiratory diseases.
Type:
Application
Filed:
July 4, 2023
Publication date:
August 7, 2025
Applicant:
CHIESI FARMACEUTICI S.P.A.
Inventors:
Elisabetta ARMANI, Sara GUARIENTO, Andrea RIZZI, Huw David VATER, Hervè Pierre Clotaire VAN DE POËL
Abstract: The present invention relates to oral compositions comprising cabozantinib salts and at least one pharmaceutically acceptable excipient and methods of using the oral compositions to increase the oral bioavailability of the cabozantinib and reduce the adverse events associate with the oral administration of cabozantinib. The invention also relates to methods for preparing cabozantinib lauryl sulfate salts.
Type:
Application
Filed:
April 21, 2025
Publication date:
August 7, 2025
Applicant:
Handa Oncology, LLC
Inventors:
Fang-Yu Liu, K.C. Sung, Yu Zhang, Shang Wei Qin, John Duan, George Kraft
Abstract: The invention relates to a compound of the following formula (I) in which X is an anion, in which R1 and R2 are either together —CH3 or a C1-C4 alkyl such that, if R1 is a Cn+i alkyl, R2 is a Cn alkyl, and vice versa, n being an integer ranging from 1 to 3, i being an integer ranging from 1 to 3 and in which n+i ranges from 1 to 4; and in which R3 is a —CH3 or a C2-C8 alkyl, said C2-C8 alkyl being optionally substituted with one or more heteroatoms.
Type:
Application
Filed:
January 23, 2023
Publication date:
August 7, 2025
Applicants:
UNIVERSITE D'AIX-MARSEILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ETAT FRANCAIS (MINIATÉRE DES ARMÉES) REPRÉSENTÉ PAR LA DIRECTION CENTRALE DU SERVICE DE SANTÉ DES AR
Inventors:
Frédéric BRUNEL, Oliver SIRI, Serhii KRYKUN, Mrunal PATIL, Michel CAMPLO, Jean-Michel BOLLA, Jean-Manuel RAIMUNDO, Frédéric GARZINO, Eric GARNOTEL
Abstract: A process for the synthesis of melamine including the purification of the offgas released by the synthesis of melamine by means of a first purification stage followed by a second purification stage (7); in the first purification stage (6) the offgas (3) is contacted with urea melt from the second stage (7) and with a recirculated urea melt (8, 9) containing ammonia and melamine precursors (5); in the second purification stage (7) the offgas from the first stage is contacted with fresh urea melt (15); said recirculated urea melt is withdrawn from bottom of the first stage and cooled in a shell and tube heat exchanger (11) to a temperature of not less than 165° C. preferably in the range 165° C. to 245° C. prior to reintroduction in said first stage.
Abstract: The present invention relates to the field of dihydromyricetin extraction and purification, and in particular to a dihydromyricetin extraction and purification process. Technical problem: the dihydromyricetin extraction and purification process aims to resolve the technical problems of increased cost of subsequent impurity removing and safety risks in high-temperature centrifugation in the prior art.
Abstract: Disclosed herein are compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R1 and R2 represent hydrogen or deuterium; R3 represents hydrogen, —COOH or —OH; R3? and R3? represent hydrogen, methyl, methoxy, chlorine, fluorine or cyano; R4 and R4? represent hydrogen or fluorine; R5 represents hydrogen, fluorine or (C1-C3)alkyl; R6 represents phenyl, fused phenyl, bicyclic group comprising 5 to 12 carbon atoms, heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, cycloalkyl group comprising 3 to 7 carbon atoms, (C3-C6)cycloalkyl(C1-C3)alkyl group, 4 to 7 membered-heterocycloalkyl group comprising 1 or 2 heteroatoms, (C1-C6)alkyl, and phenyl(C1-C2)alkyl group; X represents —CH2—, —O— or —S—; Y represents —CH?, —N? or —CR??, wherein R? represents (C1-C3)alkyl, halogen, cyano, or (C1-C3)fluoroalkyl; R7 represents (C1-C3)alkyl, halogen atom, cyano, or (C1-C3)fluoroalkyl; R8 represents hydrogen or fluorine; R9 represents hydrogen, (C1-C3)alkyl or a cyclo
Type:
Application
Filed:
April 14, 2023
Publication date:
August 7, 2025
Inventors:
Patrick BERNARDELLI, Youssef EL-AHMAD, Franck SLOWINSKI
Abstract: Described herein are benzothiazole-phenyl-sulfonyl-piperidine compounds for activating N-acyl-phosphatidylethanolamine hydrolyzing phospholipase D (NAPE-PLD).
Type:
Application
Filed:
April 14, 2023
Publication date:
August 7, 2025
Inventors:
Sean Davies, Gary A. Sulikowski, Kwangho Kim, Alex G. Waterson, Ian M. Romaine, Paige N. Vinson, Charles David Weaver, Jonah Elliot Zarrow, Geetika Aggarwal, Rocco D. Gogliotti
Abstract: The disclosure is directed to nitrogen-containing heteroaryl analogs, methods of making nitrogen-containing analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and/or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Application
Filed:
March 24, 2025
Publication date:
August 7, 2025
Applicant:
Mitokinin, Inc.
Inventors:
Daniel de Roulet, Johan Bartholomeus, Shawn Johnstone, Randall Marcelo Chin, Nicholas Thomas Hertz, Robert DeVita
Abstract: The present invention is related to a process for the preparation of relugolix, a compound of formula I, also known as N-[4-[1-[(2,6-difluoro phenyl) methyl]-5-[(dimethyl amino]-methyl]-3-(6-methoxy-3-pyridazinyl]-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidin-6-yl]phenyl]-N?-methoxyurea, or a pharmaceutically acceptable salt thereof. The present invention is also related to a process for the preparation of crystalline relugolix.
Abstract: Disclosed herein are compounds of the formulas (I) as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to contact Gram-negative bacteria. Also provided are methods of administering compounds and compositions provided herein to a patient in need thereof, for example, for the treatment or prevention of bacterial infections or diseases.
Type:
Application
Filed:
April 12, 2023
Publication date:
August 7, 2025
Applicant:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Inventors:
Poli Adi Narayana REDDY, Rishabh SHARMA, Joseph M. SALVINO
Abstract: Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
Type:
Application
Filed:
February 26, 2025
Publication date:
August 7, 2025
Inventors:
Francesco G. Salituro, Maria Jesus Blanco-Pillado, Marshall Lee Morningstar
Abstract: The present disclosure relates to anti-cancer uses utilizing an adenosine diphosphate (ADP)-ribose binding peptide and ADP-ribose. A pharmaceutical composition of the present disclosure accumulates ADP-ribose in cancer cells, thereby disrupting the cellular balance to induce cancer cell death, and having excellent anti-cancer effects, particularly in cancers that are resistant to conventional PRAP inhibitors.
Abstract: An armored seating assembly for a rotorcraft or other aircraft (e.g., for a pilot or operator) includes a wing armor panel capable of rotational and vertical movement relative to the seat base when adjusted by the operator. For example, a carriage attached to the armor panel translates along a carriage slot in the seat base, stabilized in the carriage slot by orthogonal sets of bearings (e.g., lateral bearings and longitudinal bearings) and allowing the wing armor panel to be vertically adjusted relative to the seat base (e.g., to accommodate pilots of varying heights). The armor panel is coupled to the carriage by hinges allowing the panel to pivot or rotate away from the seat base, in order to facilitate entry to and egress from the seat.
Abstract: An aircraft including at least one engine attachment system, connecting an engine and a primary structure, which includes a central body and at least first right and left extensions positioned on either side of the central body in a first transverse plane, connected to the latter and stiffened by other right and left extensions and reinforcements. The engine attachment system includes at least three connections each including an anchoring point rigidly secured to the engine, the anchoring points of the various connections being located approximately in the same transverse plane. This solution makes it possible to reduce stresses in the engine, in particular torsional and/or bending stresses, produced as a result of the transfer of the forces between the engine and the primary structure.
Type:
Application
Filed:
January 28, 2025
Publication date:
August 7, 2025
Inventors:
Frederic Journade, Olivier Pautis, Jérôme Colmagro, Germain Gueneau, Pierre-Antoine Combes, Marc De Nicola, Fabrice Grimal
Abstract: A system and method of determining emissions for an aircraft with a turbine engine for a flight mission includes receiving a control data input. The control data input can receive a quality check, and then be projected to different power levels for completion of the flight mission. The projection to different power levels can receive another quality check. The system and method generate an emissions index based on the control data input projected to different power levels representing emissions for completion of the flight mission.
Type:
Application
Filed:
February 1, 2024
Publication date:
August 7, 2025
Inventors:
Carlos Hernandez Meza, Joseph Zelina, Sharon M. Crall, Jose Manuel Rodriguez Miranda
Abstract: A method includes obtaining, using at least one processing device, real-time information associated with operation of an aircraft from one or more sensors of the aircraft. The method also includes obtaining, using the at least one processing device, additional information associated with the aircraft, where at least some of the additional information is associated with limited lifetime parts of the aircraft. The method further includes processing, using the at least one processing device, the real-time information and the additional information to generate a determination whether one or more engines of the aircraft should continue running or should be shut down and subsequently restarted. In addition, the method includes generating, using the at least one processing device, at least one output identifying how to operate the one or more engines of the aircraft based on the determination.
Abstract: In an embodiment, a payload assembly is independent of a corresponding mobile platform (e.g. small unmanned aerial vehicle (sUAV), etc.). The payload assembly includes a flight controller (FC), a global positioning system (GPS) unit, a radio frequency (RF) telemetry unit, an RF antenna, a companion computer, and a power distribution system, thereby enabling both mobile platform and payload agnostic capabilities.
Type:
Application
Filed:
February 2, 2024
Publication date:
August 7, 2025
Inventors:
Warner Allen MILLER, Michael LANGE, Victor BUCKLEW, Samuel KNARR
Abstract: A system and a method for inspection of a Region of Interest (210) include a first Unmanned Aerial Vehicle (UAV) (102) and a second UAV (104). The first UAV (102) is configured to manoeuvre to the RoI (210), and the second UAV (104) is physically coupled with the first UAV (102) through a tether and winch mechanism (106). Upon reaching the RoI (210), the second UAV (104) is configured to move from a stowed position to a deployed position with respect to the first UAV (102), such that the second UAV (104), in the deployed position, is configured to move down from the first UAV (102), and collect, through sensors (110) integrated with the second UAV (104), data associated with the RoI (210).
Abstract: A fin sealer and method to seal a radially outwardly directed fin of a tubular web structure by directing the fin through a nip between a first and a second fin sealing rollers while communicating heat to the fin through at least one of the fin sealing rollers is provided. The fin sealer is configured to maintain a nominal face-to-face relation between an outer annulus of the first fin sealing roller and an outer annulus of the second fin sealing roller with a flexible connection between a hub element of the second fin sealing roller with the outer annulus of the second fin sealing roller.
Type:
Application
Filed:
April 25, 2025
Publication date:
August 7, 2025
Applicant:
Altria Client Services LLC
Inventors:
Jarrod W. CHALKLEY, James D. EVANS, Thien Hoang NGUYEN, Patrick S. MCELHINNEY